FDA approves disintegrating Cotempla tablet for ADHD

 ADHD in the News 2017-06-22

Neos Therapeutics Inc. recently announced the FDA approved Cotempla XR-ODT, an extended-release orally disintegrating tablet, for the treatment of ADHD in children aged 6 to 17 years. “Cotempla XR-ODT offers a new methylphenidate option in ADHD management because it dissolves in the mouth with no need for chewing or drinking water. It has a clinical profile consistent with commonly prescribed methylphenidate ADHD treatments, which are generally available as capsules that must be swallowed whole,” Ann Childress, MD, president of the Center for Psychiatry and Behavioral Medicine, Las Vegas, said in a press release.